NHLBI Announces New Genetic Target for Sickle Cell Disease

Office of the Director - December 4, 2008

Researchers have identified a gene that directly affects the production of fetal hemoglobin, which is instrumental in modifying the severity of the inherited blood disorders sickle cell disease and thalassemia. The discovery could lead to breakthrough therapies for sickle cell disease and thalassemia, which could potentially eliminate the devastating and life-threatening complications of these diseases, such as severe pain, damage to the eyes and other organs, infections, and stroke.

Dr. Alan Michelson, Associate Director for Basic Research in NHLBI, through his article 'From Genetic Association to Genetic Switch' gives a scientific perspective to this significant research discovery.

For more information, please visit NHLBI Press Release.

Twitter

Facebook

YouTube